eLetters

117 e-Letters

published between 2010 and 2013

  • Our response to questions raised by Drs Ugurlu and Seyahi
    Robyn T Domsic

    We thank Drs Ugurlu and Seyahi for their comments and request for clarification regarding the development of the skin thickness progression rate. For the purpose of this study, we included only patients with early diffuse scleroderma at the time of the first Pittsburgh evaluation (<2 years duration). We defined diffuse cutaneous disease as skin thickening proximal to the elbows or knees (upper arms, thighs or trunk) o...

    Show More
  • Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Comment on the article by Domsic et al.
    Serdal Ugurlu

    To the editor, We read with interest the article by Domsic et al (1) in which they report that skin thickness progression rate (STPR) could predict mortality and early internal organ involvement in diffuse scleroderma (dSSc). There are few points that we would like to address: 1)Authors included only patients with diffuse skin involvement at the time of initial evaluation and measured STPR prospectively in 826 patients wit...

    Show More
  • Letter to Editor
    David T. Felson

    Dear Editor,

    In a recent issue of ARD, Wildi and colleagues reported results of a randomized trial and suggested that chondroitin sulfate slowed the rate of cartilage loss in osteoarthritic knees over 6 months (1). We have a number of concerns.

    The authors controlled for age and bisphosphonate use between treatment groups, but these are not known to be associated with cartilage loss. In contrast, these authors a...

    Show More
  • To the Editor:
    nathalie costedoat-chalumeau

    Dear Editor,

    We read with great interest the article of Petri et al [1] addressing the important issue of the effects of statins on vascular disease of patients with systemic lupus erythematosus (SLE). This randomized clinical trial showed no benefit of atorvastatin in the progression of subclinical atherosclerosis in 200 patients with SLE, most of them with normal lipid levels. This result is of high clinical relevance,...

    Show More
  • the risks of glucocorticoids in perspective
    Maarten Boers

    Dear Editor,

    Dixon et al have performed a careful nested case-control study of the risk of non-serious infections associated with glucocorticoid use in elderly RA patients. Their methodology is impeccable, and the limitations of the study are clearly discussed.
    Importantly, and to my satisfaction, they stress that confounding by indication cannot be ignored, although they posit that such confounding cannot complet...

    Show More
  • Successful treatment of refractory adult Still's disease with IL-6 receptor blockade
    Xavier Puechal

    Dear Editori,

    We have read with interest the letter of Rech et al. on 3 patients with adult's Still disease (ASD) who experienced systemic and arthritis improvement while being treated with tocilizumab (TCZ) (1).

    We would like to add that a previously published cohort study has reported the results of a tocilizumab treatment in all ASD patients treated in France with TCZ during a three-year period, after failure...

    Show More
  • Re:Clarification of the role of ultrasonography, magnetic resonance imaging and conventional radiography in the ACR/EULAR 2010 rheumatoid arthritis classification criteria - comment to the article by Aletaha et al.
    Daniel Aletaha

    Dear Editor,

    We thank Dr. Ostergaard for the comment on the mentioned article on the ACR/EULAR classification criteria. As co-authors on that manuscript, we confirm that all points mentioned by the authors are correct:
    - Only patients with a clinical synovitis, which is not clearly better explained by another disease entity are eligible for testing.
    - MRI and US may be used to determine a more complete joint in...

    Show More
  • Presentation of peripheral CD27++ plasma cells in systemic lupus erythematosus patients
    Deng-Ho Yang

    Dear Editor,

    I was interested in the study about CD27++ plasma cells by Ten Boekel et al., in which they evaluate longitudinal data of CD27++ plasma cells in systemic lupus erythematosus (SLE) patients. [1] There are many factors influencing the expression of peripheral CD27++ plasma cells in SLE patients, including infection and immunosuppressive drugs. [2,3] In our pervious study, although the expression of peripheral...

    Show More
  • To the Editor:
    nathalie Costedoat-Chalumeau

    Dear Editor,

    We read with great interest the article of Houssiau et al (1) that provide valuable information for the management of SLE patients with lupus nephritis. However, there is no mention on hydroxycloroquine (HCQ) use in their study. We and others strongly believe that management of SLE patients can be easily improved with more systematic use of this inexpensive drug that has a high efficacy/toxicity ratio. HCQ...

    Show More
  • Clarification of the role of ultrasonography, magnetic resonance imaging and conventional radiography in the ACR/EULAR 2010 rheumatoid arthritis classification criteria - comment to the article by Aletaha et al.
    Mikkel Ostergaard

    Dear Editor,

    With large enthusiasm I read the paper on the 2010 ACR/EULAR RA classification criteria,[1,2] which in the interest of our patients allow earlier diagnosis of rheumatoid arthritis (RA). I congratulate the authors for their hard and successfull work, which I am sure will benefit our patients.
    Being interested in imaging methods and the way they can assist rheumatologists in improving the care of patient...

    Show More

Pages